1[1]Wu CC, Ho YZ, Ho WL, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal. BrJSurg, 1995, 82 (1) :122
2[2]Lan WY, Leung TW, Ho SK, et al. Adjuvant intra - arterial iodine- 131 - labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet, 1999, 353(9155) :797
3[3]Lai EC, Lo CM, Fan ST, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial. Arch Surg, 1998, 133 (2) :183
4[4]Yamamoto M, Arii S, Sugahara K, et al. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg, 1996, 83 (3) :336
5[5]Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre - operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res, 1996, 87 (2) :206
6[6]Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology, 1994, 20(2) :295
7[7]Kwok PC, Lam TW, Lam PW, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol,2003, 18 (4) :450
8[8]Ueno S, Tanabe G, Yoshida A, et al. Postoperative prediction and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer, 1999, 86(2) :248
9[9]Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study. Semin Oncol,1997, 24 (2 Suppl 6): S6- 18:S6- 25
10[10]Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology, 1996, 43(12) : 1405
5Kar S, Wang M, Carr BI. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis, Cancer Chemother Pharmacol 2008; 62:831-840.
6Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000; 59:68-74.
7Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23:9408-9421.
8Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002; 59:126-142.
